| Enfortumab Vedotin studied in …STUDIED_INderived72 of 72show fewer |
|---|
| → studied in | NCT07421700Phase 1/Phase 2 · recruiting Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217496Phase 1 · not yet recruiting N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07475806Phase 2 · recruiting A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04225117Phase 2 · active not recruiting A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06906822Phase 2 · active not recruiting PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients · 72 trials list this drug (58 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239624Phase 2 · recruiting Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06394570Phase 1/Phase 2 · recruiting Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Bladder Urothelial Carcinoma,Invasive Bladder Giant Cell Urothelial Carcinoma,Malignant Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822373Phase 2 · not yet recruiting A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014139Phase 1 · terminated A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) · 72 trials list this drug (58 active) | — | — | Carcinoma In Situ,Transitional Cell Carcinoma,Bladder Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07566156Phase 3 · recruiting Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) · 72 trials list this drug (58 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07815665Phase 2/Phase 3 · recruiting A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06311214Phase 2 · recruiting Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) · 72 trials list this drug (58 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07287995Phase 1/Phase 2 · recruiting A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547973Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06862219Phase 4 · recruiting A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05614739Phase 1 · recruiting FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 · 72 trials list this drug (58 active) | — | — | Bladder Neoplasm,Ureter Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06011954recruiting A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection · 72 trials list this drug (58 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06041503Phase 2 · recruiting Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · 72 trials list this drug (58 active) | — | — | Testicular Germ Cell Tumor,Bladder Squamous Cell Carcinoma,Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05868265Phase 2 · active not recruiting A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891560Phase 2 · recruiting A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma · 72 trials list this drug (58 active) | — | — | Adenoid Cystic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06809140Phase 2 · recruiting Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer · 72 trials list this drug (58 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04887870Phase 2/Phase 3 · completed Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03869190Phase 1/Phase 2 · terminated Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756569Phase 2 · recruiting Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology · 72 trials list this drug (58 active) | — | — | Bladder Squamous Cell Carcinoma,Malignant Bladder Neoplasm,Malignant Renal Pelvis Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720284Phase 3 · recruiting An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091999Phase 1 · completed A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04700124Phase 3 · active not recruiting Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05775471Phase 2 · recruiting Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06356155Phase 2 · recruiting Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07139977Phase 2 · recruiting Study of EV for Recurrent Endometrial Carcinoma · 72 trials list this drug (58 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924895Phase 3 · active not recruiting Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663747Phase 2 · not yet recruiting Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07110038Phase 2 · recruiting DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma · 72 trials list this drug (58 active) | — | — | Penile Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07484022Phase 1 · recruiting Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06434350Phase 1/Phase 2 · recruiting Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647289Phase 2 · recruiting EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC · 72 trials list this drug (58 active) | — | — | Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06104618Phase 2 · recruiting Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis · 72 trials list this drug (58 active) | — | — | Penile Squamous Cell Carcinoma,Malignant Penile Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07629700NA · not yet recruiting Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR) · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04960709Phase 3 · active not recruiting Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin · 72 trials list this drug (58 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223856Phase 3 · active not recruiting Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07087860Phase 2 · recruiting Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers · 72 trials list this drug (58 active) | — | — | Renal Pelvis and Ureter Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04878029Phase 1 · recruiting Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Invasive Bladder Urothelial Carcinoma with Squamous Differentiation | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06145308Phase 2 · recruiting Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing · 72 trials list this drug (58 active) | — | — | Salivary Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553885Phase 2 · recruiting Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC · 72 trials list this drug (58 active) | — | — | Hepatocellular Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03288545Phase 1/Phase 2 · terminated A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Transitional Cell Carcinoma,Urinary Tract Neoplasm,Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05923190Phase 2 · active not recruiting Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221942Phase 2 · recruiting Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06470282Phase 1/Phase 2 · recruiting Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483334Phase 1/Phase 2 · active not recruiting A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06724159recruiting Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. · 72 trials list this drug (58 active) | — | — | Malignant Genitourinary System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04754191Phase 2 · active not recruiting Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer · 72 trials list this drug (58 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764095Phase 4 · recruiting Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial · 72 trials list this drug (58 active) | — | — | Renal Pelvis and Ureter Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07374549Phase 2 · not yet recruiting SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06305767Phase 1/Phase 2 · active not recruiting A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03474107Phase 3 · completed A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05656235Phase 2 · recruiting Renal Retention in High Grade Upper Tract Urothelial Cancer · 72 trials list this drug (58 active) | — | — | Bladder Neoplasm,Malignant Bladder Neoplasm,Urothelial Carcinoma, High Grade | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04724018Phase 1/Phase 2 · recruiting Sacituzumab Govitecan Plus EV in Metastatic UC · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm,Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04995419Phase 2 · completed A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy · 72 trials list this drug (58 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05879653Phase 2 · recruiting Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) · 72 trials list this drug (58 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524545Phase 1 · completed A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05915351Phase 2 · active not recruiting Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) · 72 trials list this drug (58 active) | — | — | Pancreatic Carcinoma,Pancreatic Adenocarcinoma,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06493552Phase 2/Phase 3 · recruiting Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904573Phase 2 · recruiting Probiotics in Advanced Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097599Phase 2 · terminated StrataPATH™ (Precision Indications for Approved Therapies) · 72 trials list this drug (58 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03070990Phase 1 · completed A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03219333Phase 2 · completed A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer · 72 trials list this drug (58 active) | — | — | Transitional Cell Carcinoma,Urinary Tract Neoplasm,Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01409135Phase 1 · completed A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 · 72 trials list this drug (58 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606174Phase 2 · terminated A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Urothelial Carcinoma,Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04136808approved for marketing An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma · 72 trials list this drug (58 active) | — | — | Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |